<!DOCTYPE html>
<!-- Generated by pkgdown: do not edit by hand --><html lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"><meta charset="utf-8"><meta http-equiv="X-UA-Compatible" content="IE=edge"><meta name="viewport" content="width=device-width, initial-scale=1.0"><!-- Inform modern browsers that this page supports both dark and light color schemes,
  and the page author prefers light. --><meta name="color-scheme" content="dark light"><script>
  // If `prefers-color-scheme` is not supported, fall back to light mode.
  // i.e. In this case, inject the `light` CSS before the others, with
  // no media filter so that it will be downloaded with highest priority.
  if (window.matchMedia("(prefers-color-scheme: dark)").media === "not all") {
    document.documentElement.style.display = "none";
    document.head.insertAdjacentHTML(
      "beforeend",
      "<link id=\"css\" rel=\"stylesheet\" href=\"https://bootswatch.com/3/flatly/bootstrap.css\" onload=\"document.documentElement.style.display = ''\">"
    );
  }
</script><title>Sorafenib Toxicity Dataset — dat.ursino2021 • metadat</title><!-- jquery --><script src="https://cdnjs.cloudflare.com/ajax/libs/jquery/3.4.1/jquery.min.js" integrity="sha256-CSXorXvZcTkaix6Yvo6HppcZGetbYMGWSFlBw8HfCJo=" crossorigin="anonymous"></script><!-- Bootstrap --><script src="https://cdnjs.cloudflare.com/ajax/libs/twitter-bootstrap/3.4.1/js/bootstrap.min.js" integrity="sha256-nuL8/2cJ5NDSSwnKD8VqreErSWHtnEP9E7AySL+1ev4=" crossorigin="anonymous"></script><!-- bootstrap-toc --><link rel="stylesheet" href="../bootstrap-toc.css"><script src="../bootstrap-toc.js"></script><!-- Font Awesome icons --><link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.12.1/css/all.min.css" integrity="sha256-mmgLkCYLUQbXn0B1SRqzHar6dCnv9oZFPEC1g1cwlkk=" crossorigin="anonymous"><link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.12.1/css/v4-shims.min.css" integrity="sha256-wZjR52fzng1pJHwx4aV2AO3yyTOXrcDW7jBpJtTwVxw=" crossorigin="anonymous"><!-- clipboard.js --><script src="https://cdnjs.cloudflare.com/ajax/libs/clipboard.js/2.0.6/clipboard.min.js" integrity="sha256-inc5kl9MA1hkeYUt+EC3BhlIgyp/2jDIyBLS6k3UxPI=" crossorigin="anonymous"></script><!-- headroom.js --><script src="https://cdnjs.cloudflare.com/ajax/libs/headroom/0.11.0/headroom.min.js" integrity="sha256-AsUX4SJE1+yuDu5+mAVzJbuYNPHj/WroHuZ8Ir/CkE0=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/headroom/0.11.0/jQuery.headroom.min.js" integrity="sha256-ZX/yNShbjqsohH1k95liqY9Gd8uOiE1S4vZc+9KQ1K4=" crossorigin="anonymous"></script><!-- pkgdown --><link href="../pkgdown.css" rel="stylesheet"><script src="../pkgdown.js"></script><!-- docsearch --><script src="../docsearch.js"></script><link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/docsearch.js/2.6.3/docsearch.min.css" integrity="sha256-QOSRU/ra9ActyXkIBbiIB144aDBdtvXBcNc3OTNuX/Q=" crossorigin="anonymous"><link href="../docsearch.css" rel="stylesheet"><script src="https://cdnjs.cloudflare.com/ajax/libs/mark.js/8.11.1/jquery.mark.min.js" integrity="sha256-4HLtjeVgH0eIB3aZ9mLYF6E8oU5chNdjU6p6rrXpl9U=" crossorigin="anonymous"></script><meta property="og:title" content="Sorafenib Toxicity Dataset — dat.ursino2021"><meta property="og:description" content="13 studies investigating the occurrence of dose limiting toxicities (DLTs) at different doses of Sorafenib."><meta name="twitter:card" content="summary_large_image"><meta name="twitter:creator" content="@wviechtb"><meta name="twitter:site" content="@wviechtb"><!-- mathjax --><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/MathJax.js" integrity="sha256-nvJJv9wWKEm88qvoQl9ekL2J+k/RWIsaSScxxlsrv8k=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/config/TeX-AMS-MML_HTMLorMML.js" integrity="sha256-84DKXVJXs0/F8OTMzX4UR909+jtl4G7SPypPavF+GfA=" crossorigin="anonymous"></script><!--[if lt IE 9]>
<script src="https://oss.maxcdn.com/html5shiv/3.7.3/html5shiv.min.js"></script>
<script src="https://oss.maxcdn.com/respond/1.4.2/respond.min.js"></script>
<![endif]--><!-- Flatly Theme - Light  --><link id="css-light" rel="stylesheet" href="https://bootswatch.com/3/flatly/bootstrap.css" media="(prefers-color-scheme: light), (prefers-color-scheme: no-preference)"><!-- Darkly Theme - Dark --><link id="css-dark" rel="stylesheet" href="https://bootswatch.com/3/darkly/bootstrap.css" media="(prefers-color-scheme: dark)"><!-- preferably CSS --><link rel="stylesheet" href="../preferably.css"><link id="css-code-light" rel="stylesheet" href="../code-color-scheme-light.css" media="(prefers-color-scheme: light), (prefers-color-scheme: no-preference)"><link id="css-code-dark" rel="stylesheet" href="../code-color-scheme-dark.css" media="(prefers-color-scheme: dark)"><script src="../darkswitch.js"></script></head><body data-spy="scroll" data-target="#toc">


    <div class="container template-reference-topic">
      <header><div class="navbar navbar-default navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-target="#navbar" aria-expanded="false">
        <span class="sr-only">Toggle navigation</span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <span class="navbar-brand">
        <a class="navbar-link" href="../index.html">metadat</a>
        <span class="version label label-default" data-toggle="tooltip" data-placement="bottom" title="">1.5-0</span>
      </span>
    </div>

    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav"><li>
  <a href="../index.html">
    <span class="fa fa-home fa-lg"></span>

  </a>
</li>
<li>
  <a href="../reference/index.html">Datasets / Functions</a>
</li>
<li>
  <a href="../news/index.html">Changelog</a>
</li>
      </ul><ul class="nav navbar-nav navbar-right"><li>
          <a href="#" id="css-toggle-btn">
            <span class="fas fa-adjust fa-lg"></span>
          </a>
        </li>

        <li>
  <a href="https://scholar.social/@wviechtb" class="external-link">Mastodon</a>
</li>
<li>
  <a href="https://github.com/wviechtb/metadat" class="external-link">GitHub</a>
</li>




      </ul><form class="navbar-form navbar-right hidden-xs hidden-sm" role="search">
        <div class="form-group">
          <input type="search" class="form-control" name="search-input" id="search-input" placeholder="Search..." aria-label="Search for..." autocomplete="off"></div>
      </form>

    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->



      </header><div class="row">
  <div class="col-md-9 contents">
    <div class="page-header">
    <h1>Sorafenib Toxicity Dataset</h1>

    <div class="hidden name"><code>dat.ursino2021.Rd</code></div>
    </div>

    <div class="ref-description">
    <p>13 studies investigating the occurrence of dose limiting toxicities (DLTs) at different doses of Sorafenib.</p>
    </div>

    <div id="ref-usage">
    <div class="sourceCode"><pre class="sourceCode r"><code><span><span class="va">dat.ursino2021</span></span></code></pre></div>
    </div>

    <div id="format">
    <h2>Format</h2>
    <p>The data frame contains the following columns:</p><table class="table table"><tr><td><b>study</b></td><td><code>character</code></td><td>study label</td></tr><tr><td><b>year</b></td><td><code>integer</code></td><td>publication year</td></tr><tr><td><b>dose</b></td><td><code>numeric</code></td><td>dose (\(\mathrm{mg}\))</td></tr><tr><td><b>events</b></td><td><code>integer</code></td><td>number of DLTs</td></tr><tr><td><b>total</b></td><td><code>integer</code></td><td>number of patients exposed</td></tr></table></div>
    <div id="details">
    <h2>Details</h2>
    <p>Sorafenib (BAY 43-9006, Nexavar) is a kinase inhibitor that is used in the treatment of advanced renal cell carcinoma, hepatocellular carcinoma, and radioactive iodine resistant advanced thyroid carcinoma. Thirteen trials with published results, described in eleven manuscripts, were identified in a literature search. This dataset contains the doses investigated, the numbers of patients treated, and the number of dose-limiting toxicities (DLTs) observed. In general, each study investigated several doses according to some dose-escalation scheme.</p>
    </div>
    <div id="source">
    <h2>Source</h2>
    <p>Ursino, M., Roever, C., Zohar,  S., &amp; Friede T. (2021). Random-effects meta-analysis of phase I dose-finding studies using stochastic process priors. <em>The Annals of Applied Statistics</em>, <b>15</b>(1), 174–193. <a href="https://doi.org/10.1214/20-AOAS1390" class="external-link">https://doi.org/10.1214/20-AOAS1390</a></p>
<p>Roever, C., Ursino, M., Friede, T., &amp; Zohar, S. (2022). A straighforward meta-analysis approach for oncology phase I dose-finding studies. <em>Statistics in Medicine</em>, <b>41</b>(20), 3915–3940. <a href="https://doi.org/10.1002/sim.9484" class="external-link">https://doi.org/10.1002/sim.9484</a></p>
    </div>
    <div id="references">
    <h2>References</h2>
    <p>European Medicines Agency (EMA) (2022). Nexavar (sorafenib) EPAR summary. <a href="https://www.ema.europa.eu/en/medicines/human/EPAR/nexavar" class="external-link">https://www.ema.europa.eu/en/medicines/human/EPAR/nexavar</a></p>
<p>Awada, A., Hendlisz, A., Gil, T., <em>et al.</em> (2005). Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on / 7 days off in patients with advanced, refractory solid tumours. <em>British Journal of Cancer</em>, <b>92</b>(10), 1855. <a href="https://doi.org/10.1038/sj.bjc.6602584" class="external-link">https://doi.org/10.1038/sj.bjc.6602584</a></p>
<p>Clark, J. W., Eder, J. P., Ryan, D., Lathia, C., &amp; Lenz, H.-J. (2005). Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. <em>Clinical Cancer Research</em>, <b>11</b>(15), 5472–5480. <a href="https://doi.org/10.1158/1078-0432.CCR-04-2658" class="external-link">https://doi.org/10.1158/1078-0432.CCR-04-2658</a></p>
<p>Moore, M., Hirte, H. W., Siu, L., <em>et al.</em> (2005). Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on / 7 days off in patients with advanced, refractory solid tumors. <em>Annals of Oncology</em>, <b>16</b>(10), 1688–1694. <a href="https://doi.org/10.1093/annonc/mdi310" class="external-link">https://doi.org/10.1093/annonc/mdi310</a></p>
<p>Strumberg, D., Richly, H., Hilger, R. A., <em>et al.</em> (2005). Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. <em>Journal of Clinical Oncology</em>, <b>23</b>(5), 965–972. <a href="https://doi.org/10.1200/JCO.2005.06.124" class="external-link">https://doi.org/10.1200/JCO.2005.06.124</a></p>
<p>Furuse, J., Ishii, H., Nakachi, K., Suzuki, E., Shimizu, S., &amp; Nakajima, K. (2008). Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. <em>Cancer Science</em>, <b>99</b>(1), 159–165. <a href="https://doi.org/10.1111/j.1349-7006.2007.00648.x" class="external-link">https://doi.org/10.1111/j.1349-7006.2007.00648.x</a></p>
<p>Minami, H., Kawada, K., Ebi, H., <em>et al.</em> (2008). Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors. <em>Cancer Science</em>, <b>99</b>(7), 1492–1498. <a href="https://doi.org/10.1111/j.1349-7006.2008.00837.x" class="external-link">https://doi.org/10.1111/j.1349-7006.2008.00837.x</a></p>
<p>Miller, A. A., Murry, D. J., Owzar, K., <em>et al.</em> (2009). Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. <em>Journal of Clinical Oncology</em>, <b>27</b>(11), 1800. <a href="https://doi.org/10.1200/JCO.2008.20.0931" class="external-link">https://doi.org/10.1200/JCO.2008.20.0931</a></p>
<p>Crump, M., Hedley, D., Kamel-Reid, S., <em>et al.</em> (2010). A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: A NCIC (National Cancer Institute of Canada) Clinical Trials Group Study. <em>Leukemia and Lymphoma</em>, <b>51</b>(2), 252–260. <a href="https://doi.org/10.3109/10428190903585286" class="external-link">https://doi.org/10.3109/10428190903585286</a></p>
<p>Borthakur, G., Kantarjian, H., Ravandi, F., <em>et al.</em> (2011). Phase I study of sorafenib in patients with refractory or relapsed acute Leukemias. <em>Haematologica</em>, <b>96</b>(1), 62–68. <a href="https://doi.org/10.3324/haematol.2010.030452" class="external-link">https://doi.org/10.3324/haematol.2010.030452</a></p>
<p>Nabors, L. B., Supko, J. G., Rosenfeld, M., <em>et al.</em> (2011). Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma. <em>Neuro-Oncology</em>, <b>13</b>(12), 1324–1330. <a href="https://doi.org/10.1093/neuonc/nor145" class="external-link">https://doi.org/10.1093/neuonc/nor145</a></p>
<p>Chen, Y.-B., Li, S., Lane, A. A., <em>et al.</em> (2014). Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for FMS-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia. <em>Biology of Blood and Marrow Transplantation</em>, <b>20</b>(12), 2042–2048. <a href="https://doi.org/10.1016/j.bbmt.2014.09.007" class="external-link">https://doi.org/10.1016/j.bbmt.2014.09.007</a></p>
    </div>
    <div id="see-also">
    <h2>See also</h2>
    <div class="dont-index"><p><code><a href="dat.roever2022.html">dat.roever2022</a></code></p></div>
    </div>
    <div id="author">
    <h2>Author</h2>
    <p>Christian Roever, <a href="mailto:christian.roever@med.uni-goettingen.de">christian.roever@med.uni-goettingen.de</a></p>
    </div>
    <div id="concepts">
    <h2>Concepts</h2>
    <p>medicine, oncology, dose-response models</p>
    </div>

    <div id="ref-examples">
    <h2>Examples</h2>
    <div class="sourceCode"><pre class="sourceCode r"><code><span class="r-in"><span><span class="co"># show (some) data</span></span></span>
<span class="r-in"><span><span class="fu"><a href="https://rdrr.io/r/utils/head.html" class="external-link">head</a></span><span class="op">(</span><span class="va">dat.ursino2021</span>, n<span class="op">=</span><span class="fl">15</span><span class="op">)</span></span></span>
<span class="r-out co"><span class="r-pr">#&gt;</span>    study year dose events total</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 1  Awada 2005  100      0     4</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 2  Awada 2005  200      0     3</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 3  Awada 2005  300      1     5</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 4  Awada 2005  400      1    10</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 5  Awada 2005  600      7    12</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 6  Awada 2005  800      1     3</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 7  Clark 2005  100      0     3</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 8  Clark 2005  200      0     3</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 9  Clark 2005  400      1     4</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 10 Clark 2005  600      1     6</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 11 Clark 2005  800      3     3</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 12 Moore 2005  100      0     3</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 13 Moore 2005  200      1     6</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 14 Moore 2005  400      0     8</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 15 Moore 2005  600      3     7</span>
<span class="r-in"><span></span></span>
<span class="r-in"><span><span class="co"># illustrate data</span></span></span>
<span class="r-in"><span><span class="fu"><a href="https://rdrr.io/r/graphics/plot.default.html" class="external-link">plot</a></span><span class="op">(</span><span class="cn">NA</span>, xlim<span class="op">=</span><span class="fu"><a href="https://rdrr.io/r/base/range.html" class="external-link">range</a></span><span class="op">(</span><span class="va">dat.ursino2021</span><span class="op">$</span><span class="va">dose</span><span class="op">)</span>, ylim<span class="op">=</span><span class="fl">0</span><span class="op">:</span><span class="fl">1</span>,</span></span>
<span class="r-in"><span>     xlab<span class="op">=</span><span class="st">"dose (mg)"</span>, ylab<span class="op">=</span><span class="st">"proportion"</span>,</span></span>
<span class="r-in"><span>     main<span class="op">=</span><span class="st">"dat.ursino2021 (Sorafenib data)"</span><span class="op">)</span></span></span>
<span class="r-in"><span><span class="va">studylab</span> <span class="op">&lt;-</span> <span class="fu"><a href="https://rdrr.io/r/base/unique.html" class="external-link">unique</a></span><span class="op">(</span><span class="va">dat.ursino2021</span><span class="op">$</span><span class="va">study</span><span class="op">)</span></span></span>
<span class="r-in"><span><span class="va">colvec</span> <span class="op">&lt;-</span> <span class="fu"><a href="https://rdrr.io/r/grDevices/palettes.html" class="external-link">rainbow</a></span><span class="op">(</span><span class="fu"><a href="https://rdrr.io/r/base/length.html" class="external-link">length</a></span><span class="op">(</span><span class="va">studylab</span><span class="op">)</span><span class="op">)</span></span></span>
<span class="r-in"><span><span class="kw">for</span> <span class="op">(</span><span class="va">i</span> <span class="kw">in</span> <span class="fl">1</span><span class="op">:</span><span class="fu"><a href="https://rdrr.io/r/base/length.html" class="external-link">length</a></span><span class="op">(</span><span class="va">studylab</span><span class="op">)</span><span class="op">)</span> <span class="op">{</span></span></span>
<span class="r-in"><span>  <span class="va">idx</span> <span class="op">&lt;-</span> <span class="op">(</span><span class="va">dat.ursino2021</span><span class="op">$</span><span class="va">study</span> <span class="op">==</span> <span class="va">studylab</span><span class="op">[</span><span class="va">i</span><span class="op">]</span><span class="op">)</span></span></span>
<span class="r-in"><span>  <span class="fu"><a href="https://rdrr.io/r/graphics/lines.html" class="external-link">lines</a></span><span class="op">(</span><span class="va">dat.ursino2021</span><span class="op">[</span><span class="va">idx</span>,<span class="st">"dose"</span><span class="op">]</span>,</span></span>
<span class="r-in"><span>        <span class="va">dat.ursino2021</span><span class="op">[</span><span class="va">idx</span>,<span class="st">"events"</span><span class="op">]</span> <span class="op">/</span> <span class="va">dat.ursino2021</span><span class="op">[</span><span class="va">idx</span>,<span class="st">"total"</span><span class="op">]</span>,</span></span>
<span class="r-in"><span>        col<span class="op">=</span><span class="va">colvec</span><span class="op">[</span><span class="va">i</span><span class="op">]</span>, type<span class="op">=</span><span class="st">"b"</span><span class="op">)</span></span></span>
<span class="r-in"><span><span class="op">}</span></span></span>
<span class="r-in"><span><span class="fu"><a href="https://rdrr.io/r/graphics/legend.html" class="external-link">legend</a></span><span class="op">(</span><span class="st">"topleft"</span>, <span class="va">studylab</span>, col<span class="op">=</span><span class="va">colvec</span>, pch<span class="op">=</span><span class="fl">15</span><span class="op">)</span></span></span>
<span class="r-plt img"><img src="dat.ursino2021-1.png" alt="" width="1728" height="1536"></span>
</code></pre></div>
    </div>
  </div>
  <div class="col-md-3 hidden-xs hidden-sm" id="pkgdown-sidebar">
    <nav id="toc" data-toggle="toc" class="sticky-top"><h2 data-toc-skip>Contents</h2>
    </nav></div>
</div>


      <footer><div class="copyright">
  <p></p><p>Developed by Wolfgang Viechtbauer, Thomas White, Daniel Noble, Alistair Senior, W. Kyle Hamilton.</p>
</div>

<div class="pkgdown">
  <p></p><p>Site built with <a href="https://pkgdown.r-lib.org/" class="external-link">pkgdown</a> 2.1.1.9000.</p>
  <p class="preferably">Using <a href="https://preferably.amirmasoudabdol.name/?source=footer" class="external-link">preferably</a> template.</p>
</div>

      </footer></div>


<script src="https://cdnjs.cloudflare.com/ajax/libs/docsearch.js/2.6.1/docsearch.min.js" integrity="sha256-GKvGqXDznoRYHCwKXGnuchvKSwmx9SRMrZOTh2g4Sb0=" crossorigin="anonymous"></script><script>
  docsearch({
    appId: 'B3DHC2OOU8',

    apiKey: '8c74dd1e0cd05800bf9f222777e07625',
    indexName: 'wviechtb-metadat',
    inputSelector: 'input#search-input.form-control',
    transformData: function(hits) {
      return hits.map(function (hit) {
        hit.url = updateHitURL(hit);
        return hit;
      });
    }
  });
</script></body></html>

